Senseonics rolls out Eversense 365 integrated with Sequel's twiist AID system, aiming to boost CGM adoption with its year-long wear advantage.
Senseonics (SENS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Senseonics (SENS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Senseonics stock jumps after Eversense 365 wins CE Mark, expanding Europe access for its one-year CGM and strengthening the long-term growth outlook.
Senseonics shares gain after Eversense 365 became the first one-year implantable CGM integrated with an automated insulin delivery system.
Senseonics Holdings earns a buy rating as Eversense 365 drives potential product-market fit and margin expansion. SENS's integration of Ascensia's commercial team and DTC investments is expected to boost revenue and gross margins above 50%. Q3 revenue grew 90% YoY, with a 42.8% gross margin and 55% YoY revenue growth guided for 2025.
Senseonics Holdings, Inc. ( SENS ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Tim Goodnow - President, CEO & Director Frederick Sullivan - CFO, Secretary & Treasurer Conference Call Participants Jeremy Feffer - Lifesci Advisors, LLC Matthew Miksic - Barclays Bank PLC, Research Division Joshua Jennings - TD Cowen, Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division Jayson Bedford - Raymond James & Associates, Inc., Research Division Xun Lee - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, everyone, and welcome to today's Senseonics Third Quarter 2025 Earnings Conference Call.
Senseonics Holdings (SENS) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.8 per share a year ago.
Senseonics (SENS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Senseonics Holdings, Inc. (NYSE:SENS ) Eversense 365 Commercial Update Conference Company Participants Tim Goodnow - President, CEO & Director Frederick Sullivan - CFO, Secretary & Treasurer Conference Call Participants Jeremy Feffer - Lifesci Advisors, LLC Brian Hansen - Ascensia Diabetes Care Us Inc. Matthew Miksic - Barclays Bank PLC, Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Joshua Jennings - TD Cowen, Research Division Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division Jayson Bedford - Raymond James & Associates, Inc., Research Division Xun Lee - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, everyone, and welcome to the Eversense 365 Commercial Update Call.
Senseonics (SENS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Senseonics Holdings, Inc. (NYSE:SENS ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Frederick T. Sullivan - CFO, Secretary & Treasurer Mukul Jain - Chief Operating Officer Timothy T.